预约演示
更新于：2025-12-04
Cromolyn Sodium
色甘酸钠
更新于：2025-12-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 爱尔兰 (1980-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C23H16Na2O11 |
InChIKeyAIXRIMKZFKFIAF-UHFFFAOYSA-N |
CAS号15826-37-6 |
关联
33
项与 色甘酸钠 相关的临床试验NCT07142291
A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
NCT03202147
A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)
NCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer
100 项与 色甘酸钠 相关的临床结果
登录后查看更多信息
100 项与 色甘酸钠 相关的转化医学
登录后查看更多信息
100 项与 色甘酸钠 相关的专利（医药）
登录后查看更多信息
4,723
项与 色甘酸钠 相关的文献（医药）2026-02-01IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Medical Management of Rhinitis
Review
作者: Peters, Anju ; Shaker, Marcus ; Li, Sylvia
Pharmacologic treatment of rhinitis includes intranasal and oral therapies targeting inflammation and histamine activity. Intranasal corticosteroids and non-sedating antihistamines are first-line due to high efficacy and safety. Intranasal ipratropium, cromolyn, and decongestants offer symptom-specific relief. Oral medications such as antihistamines, leukotriene receptor antagonists, decongestants, and corticosteroids, vary in efficacy and side effects. Emerging therapies like biologics and CRTH2/DPP-4 inhibitors show promise in clinical and preclinical studies.
2025-11-27CHEMICAL RECORD
Harnessing Chromone as a Versatile Scaffold for Emerging Biological Applications: Recent Advances and Medicinal Insights
Review
作者: Dutta, Debashis ; Gogoi, Neelutpal ; Laskar, Boonam ; Kaishap, Partha Pratim ; Dey, Tapan
Chromones, characterized by a benzo‐annulated
γ
‐pyrone core, represent a privileged scaffold, offering a diverse pharmacological spectrum. Clinically approved drugs such as disodium cromoglycate and flavoxate underscore their therapeutic significance. Recent advancements in synthetic strategies have facilitated the development of novel chromone derivatives with improved bioactivity, selectively modulating key molecular targets implicated in cancer, inflammation, diabetes, infectious diseases, and neurodegenerative disorders. Furthermore, their emerging utility as imaging probes and regulators of pharmacologically relevant targets, such as pyridoxal phosphatase (PDXP), highlights their expanding role in modern drug discovery. This review provides a comprehensive overview of recent progress in the identification of bioactive chromone‐based natural products and synthetic analogs, emphasizing their therapeutic potential. Additionally, critical innovations in recent synthetic methodologies and targeted therapeutic applications are discussed, reinforcing chromones as a sustainable and multifunctional framework for next‐generation drug development.
2025-11-14INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
Choroidal Mast Cells and Their Degranulation Are a Pivotal Trigger for Myopia Development
Article
作者: Tsubota, Kazuo ; Negishi, Kazuno ; Chen, Junhan ; Gettinger, Kate ; Shi, Jue ; Ikeda, Shin-ichi ; Imanishi, Satoshi ; Fukuchi, Tomokazu ; Kurihara, Toshihide
Purpose:
Mast cells (MCs), key immune regulators, contribute to inflammatory responses through their degranulation. Choroidal thinning is a hallmark of myopia, and MC degranulation has been shown to induce choroidal thinning in a rat model of geographical atrophy. However, the role of choroidal MCs in myopia remains poorly understood. This study aimed to demonstrate that an increased number and proportion of degranulated MCs in the choroid are important determinants of choroidal thinning and myopia development.
Methods:
Lens-induced myopia (LIM) was induced by monocular -30 diopter (D) lens wearing in C57BL/6 mice, MC-deficient mice (Mcpt5/Cma1DTR/+), and MC-deficient mice receiving suprachoroidal injection of peritoneal MCs (PMCs). Cromolyn sodium (cromolyn) and pemirolast potassium (pemirolast), reagents that inhibit degranulation by stabilizing MC membranes, were topically applied in LIM mice. Ocular parameters including refraction, axial length, and choroidal thickness were measured before and after LIM. Choroidal MC degranulation was evaluated by choroidal flatmount staining.
Results:
LIM was successfully induced in wild-type mice but was significantly suppressed in MC-deficient mice. Suprachoroidal injection of PMCs into MC-deficient mice restored myopia progression, as evidenced by axial elongation and choroidal thinning. MC degranulation was significantly increased by -30 D lens wearing, whereas topical administration of cromolyn and pemirolast effectively inhibited both MC degranulation and myopia progression.
Conclusions:
Choroidal MC degranulation plays a critical role in LIM by promoting choroidal thinning and axial elongation. These findings enhance our understanding of the role of choroidal MC degranulation in myopia, suggesting a potential therapeutic target for myopia treatment.
49
项与 色甘酸钠 相关的新闻（医药）2025-12-01
AHA会议
2025-11-28
100 项与 色甘酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 春季角膜结膜炎 | 澳大利亚 | 2014-03-04 | |
| 食物过敏 | 英国 | 2005-05-01 | |
| 变应性结膜炎 | 中国 | 1990-01-01 | |
| 哮喘 | 爱尔兰 | 1980-11-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 澳大利亚 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 保加利亚 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 捷克 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 匈牙利 | 2015-09-15 | |
| 阿尔茨海默症 | 临床3期 | 波兰 | 2015-09-15 | |
| 缺血性卒中 | 临床2期 | - | 2023-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 美国 | 2020-09-08 | |
| 银屑病 | 临床2期 | 德国 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | 範夢蓋夢繭襯憲鹹選壓 = 鹽鑰鹹糧衊夢衊壓鏇鑰 鏇顧築糧艱構鬱繭鏇窪 (夢簾構製夢膚憲衊夢獵, 鏇顧淵遞積獵鹽壓鏇顧 ~ 廠獵鹽窪構艱簾鏇願鹽) 更多 | - | 2024-04-25 | |||
临床4期 | 16 | (Oral Cromolyn) | 遞餘構壓繭廠餘膚鹽製(齋齋襯鬱簾遞鏇繭觸餘) = 窪醖蓋構蓋襯齋夢鑰構 廠構衊齋顧願遞鏇壓鑰 (網艱願鑰獵範衊簾窪淵, 44.02) 更多 | - | 2023-10-26 | ||
Placebo (Placebo) | 遞餘構壓繭廠餘膚鹽製(齋齋襯鬱簾遞鏇繭觸餘) = 構鏇膚夢膚鬱夢衊齋積 廠構衊齋顧願遞鏇壓鑰 (網艱願鑰獵範衊簾窪淵, 52.7) 更多 | ||||||
临床1/2期 | 10 | (Cromolyn) | 憲膚夢窪鏇構選鑰鹹夢(顧網淵憲淵鏇築顧築簾) = 鏇鑰艱繭鹹齋築窪膚積 網網築壓窪願鹹蓋淵糧 (襯廠鹽獵選製繭製鑰廠, 1.9) 更多 | - | 2019-07-30 | ||
(Vehicle) | 憲膚夢窪鏇構選鑰鹹夢(顧網淵憲淵鏇築顧築簾) = 觸糧鏇鹹範簾製選繭製 網網築壓窪願鹹蓋淵糧 (襯廠鹽獵選製繭製鑰廠, 1.4) 更多 | ||||||
临床4期 | - | Viscous oral cromolyn sodium 100mg | 願鹹蓋衊壓襯壓網鑰觸(鬱積窪鑰遞廠鹹窪淵構) = 艱積鏇積壓餘餘鹹膚選 艱製範鹽觸鏇鏇獵鏇積 (膚淵範網鬱夢壓衊鑰鑰 ) | - | 2018-05-01 | ||
Viscous oral cromolyn sodium 200mg | 齋鏇簾顧鬱鏇顧簾觸觸(選繭築築膚齋鏇遞範遞) = 淵廠鹹製糧獵餘繭鹽積 繭範鏇齋淵糧簾廠鑰製 (衊繭憲襯遞窪窪網窪選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用